Knockdown of GBP5 alleviates renal damage caused by psoriasis by regulating NF-κB/STAT3 pathway
Main Article Content
Keywords
GBP5, Inflammation, NF-κB/STAT3 pathway, psoriasis, renal damage
Abstract
Background: Kidney impairment resulting from psoriasis constitutes a serious complication, affecting the overall well-being of patients and necessitating a thorough comprehension for efficient management. Guanylate-binding protein 5 (GBP5) is known to play a role in inflammatory responses, but its function in psoriasis remains unclear and warrants investigation in.
Objective: To pinpoint GBP5 as innovative therapeutic target and decipher the underlying mechanisms in kidney impairment resulting from psoriasis.
Methods: Skin samples from psoriatic patients were used to detect GBP5 expression through Immunoblot and qPCR. Hacat cells were treated with TNF-α to construct the psoriasis skin cell model. Edu and CCK-8 assays were performed to confirm the effects on cell viability, ELISA was conducted to confirm the effects on inflammation. H&E staining and PASI scocing were conducted to confirm the effects on renal damage. Immunoblot confirmed the mechanism.
Results: GBP5 was highly expressed in psoriasis skin tissues. Ablation of GBP5 reduced tumor necrosis factor alpha (TNF-α)-stimulated growth as well as inflammation in human immortalized keratinocyte (HaCaT) cell. In the imiquimod (IMQ)-stimulated mouse model, GBP5 knockdown alleviated psoriasis symptoms and reduced renal damage. Mechanically, GBP5 depletion suppressed the activation of nuclear factor kappa-light-chain-enhancer of activated B cells–signal transducer and activator of transcription 3 (NF-κB/STAT3) axis.
Conclusion: Inhibiting GBP5 can mitigate the renal injury caused by psoriasis through NF-κB/STAT3 axix.
References
2. Rendon A, Schakel K. Psoriasis pathogenesis and treatment. Int J Mol Sci. 2019;20(6):1475. 10.3390/ijms20061475
3. Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: A review. JAMA. 2020;323(19):1945–60. 10.1001/jama.2020.4006
4. Langley RG, Krueger GG, Griffiths CE. Psoriasis: Epidemiology, clinical features, and quality of life. Ann Rheum Dis. 2005;64(Suppl 2):ii18–23; discussion ii4–5. 10.1136/ard.2004.033217
5. Krupka-Olek M, Bozek A, Drewienkowska M, Dryjka K, Medrala A. Immunological differences between atopic dermatitis, psoriasis, and their combination in adult patients. Allergol Immunopathol (Madr). 2022;50(4):143–6. 10.15586/aei.v50i4.557
6. Ahamad N, Kar A, Mehta S, Dewani M, Ravichandran V, Bhardwaj P, et al. Immunomodulatory nanosystems for treating inflammatory diseases. Biomaterials. 2021;274:120875. 10.1016/j.biomaterials.2021.120875
7. Ka-Eun Kim N-RS, Soon-Hi Park, Sang-Yun Nam, Yong-Soon Yoon, Soon-Kwon Park, Jeong-Sook Park, Il-Young Cho. Modulation of the human immune status by spinal thermal massage: A non-randomized controlled study. Signa Vitae. 2021;18(2):137–46. 10.22514/sv.2021.144
8. Tashiro T, Sawada Y. Psoriasis and systemic inflammatory disorders. Int J Mol Sci. 2022;23(8):4457. 10.3390/ijms23084457
9. Yu H, Lin L, Zhang Z, Zhang H, Hu H. Targeting NF-kappaB pathway for the therapy of diseases: Mechanism and clinical study. Signal Transduct Target Ther. 2020;5(1):209. 10.1038/s41392-020-00312-6
10. Salas A, Hernandez-Rocha C, Duijvestein M, Faubion W, McGovern D, Vermeire S, et al. JAK-STAT pathway targeting for the treatment of inflammatory bowel disease. Nat Rev Gastroenterol Hepatol. 2020;17(6):323–37. 10.1038/s41575-020-0273-0
11. Zhang D, Jing B, Chen ZN, Li X, Shi HM, Zheng YC, et al. Ferulic acid alleviates sciatica by inhibiting neuroinflammation and promoting nerve repair via the TLR4/NF-kappaB pathway. CNS Neurosci Ther. 2023;29(4):1000–11. 10.1111/cns.14060
12. Xu Z, Li J, Zhou K, Wang K, Hu H, Hu Y, et al. Exocarpium citri grandis ameliorates LPS-induced acute lung injury by suppressing inflammation, NLRP3 inflammasome, and ferroptosis. J Ethnopharmacol. 2024;329:118162. 10.1016/j.jep.2024.118162
13. Li JM, Deng HS, Yao YD, Wang WT, Hu JQ, Dong Y, et al. Sinomenine ameliorates collagen-induced arthritis in mice by targeting GBP5 and regulating the P2X7 receptor to suppress NLRP3-related signaling pathways. Acta Pharmacol Sin. 2023;44(12):2504–24. 10.1038/s41401-023-01124-4
14. Liu N, Gao Y, Liu Y, Liu D. GBP5 inhibition ameliorates the progression of lupus nephritis by suppressing NLRP3 inflammasome activation. Immunol Invest. 2023;52(1):52–66. 10.1080/08820139.2022.2122834
15. Zhou L, Zhao H, Zhao H, Meng X, Zhao Z, Xie H, et al. GBP5 exacerbates rosacea-like skin inflammation by skewing macrophage polarization towards M1 phenotype through the NF-kappaB signalling pathway. J Eur Acad Dermatol Venereol. 2023;37(4):796–809. 10.1111/jdv.18725
16. Cao FY, Wang CH, Li X, Ma MZ, Tao GC, Yang C, et al. Guanylate binding protein 5 accelerates gastric cancer progression via the JAK1-STAT1/GBP5/CXCL8 positive feedback loop. Am J Cancer Res. 2023;13(4):1310–28.
17. Xu J, Chen A, Peng Y, Wen Z, Huang K, Wang P. A case report of adalimumab successfully treated a severe plaque psoriasis patient with psoriatic end-stage renal disease. Clin Cosmet Investig Dermatol. 2023;16:2841–6. 10.2147/CCID.S420900
18. Thatikonda S, Pooladanda V, Sigalapalli DK, Godugu C. Piperlongumine regulates epigenetic modulation and alleviates psoriasis-like skin inflammation via inhibition of hyperproliferation and inflammation. Cell Death Dis. 2020;11(1):21. 10.1038/s41419-019-2212-y
19. Ding K, Li X, Ren X, Ding N, Tao L, Dong X, et al. GBP5 promotes liver injury and inflammation by inducing hepatocyte apoptosis. FASEB J. 2022;36(1):e22119. 10.1096/fj.202101448R
20. Zhong K, Liu K, Song Y, Chen S, Hu X, Xue R, et al. A synthetic steroid 5 alpha-androst-3beta, 5, 6beta-triol alleviates radiation-induced brain injury in mice via inhibiting GBP5/NF-kappaB/NLRP3 signal axis. Mol Neurobiol. 2024;61(7):4074–89. 10.1007/s12035-023-03831-9
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.